School of Dentistry, College of Oral Medicine, Taipei Medical University, Taipei, 110301, Taiwan.
Department of Traditional Chinese Medicine, Chang Gung Memorial Hospital at Taoyuan, Taoyuan, 333008, Taiwan.
Cell Commun Signal. 2024 Feb 15;22(1):125. doi: 10.1186/s12964-024-01501-4.
The activation of peroxisome proliferator-activated receptor (PPAR)-γ has been extensively shown to attenuate inflammatory responses in conditions such as asthma, acute lung injury, and acute respiratory distress syndrome, as demonstrated in animal studies. However, the precise molecular mechanisms underlying these inhibitory effects remain largely unknown. The upregulation of heme oxygenase-1 (HO-1) has been shown to confer protective effects, including antioxidant, antiapoptotic, and immunomodulatory effects in vitro and in vivo. PPARγ is highly expressed not only in adipose tissues but also in various other tissues, including the pulmonary system. Thiazolidinediones (TZDs) are highly selective agonists for PPARγ and are used as antihyperglycemic medications. These observations suggest that PPARγ agonists could modulate metabolism and inflammation. Several studies have indicated that PPARγ agonists may serve as potential therapeutic candidates in inflammation-related diseases by upregulating HO-1, which in turn modulates inflammatory responses. In the respiratory system, exposure to external insults triggers the expression of inflammatory molecules, such as cytokines, chemokines, adhesion molecules, matrix metalloproteinases, and reactive oxygen species, leading to the development of pulmonary inflammatory diseases. Previous studies have demonstrated that the upregulation of HO-1 protects tissues and cells from external insults, indicating that the induction of HO-1 by PPARγ agonists could exert protective effects by inhibiting inflammatory signaling pathways and attenuating the development of pulmonary inflammatory diseases. However, the mechanisms underlying TZD-induced HO-1 expression are not well understood. This review aimed to elucidate the molecular mechanisms through which PPARγ agonists induce the expression of HO-1 and explore how they protect against inflammatory and oxidative responses.
过氧化物酶体增殖物激活受体 (PPAR)-γ 的激活已被广泛证明可减轻哮喘、急性肺损伤和急性呼吸窘迫综合征等疾病中的炎症反应,这在动物研究中得到了证实。然而,这些抑制作用的确切分子机制在很大程度上仍然未知。血红素加氧酶-1 (HO-1) 的上调已被证明具有保护作用,包括在体外和体内的抗氧化、抗凋亡和免疫调节作用。PPARγ 不仅在脂肪组织中高度表达,而且在包括肺部系统在内的各种其他组织中也高度表达。噻唑烷二酮类 (TZDs) 是 PPARγ 的高度选择性激动剂,被用作抗高血糖药物。这些观察结果表明,PPARγ 激动剂可以通过调节代谢和炎症来发挥作用。几项研究表明,PPARγ 激动剂通过上调 HO-1 来调节炎症反应,从而可能成为炎症相关疾病的潜在治疗候选药物。在呼吸系统中,暴露于外部刺激会引发炎症分子(如细胞因子、趋化因子、粘附分子、基质金属蛋白酶和活性氧)的表达,从而导致肺部炎症性疾病的发展。先前的研究表明,HO-1 的上调可保护组织和细胞免受外部刺激,表明 PPARγ 激动剂诱导的 HO-1 表达可通过抑制炎症信号通路和减轻肺部炎症性疾病的发展来发挥保护作用。然而,TZDs 诱导的 HO-1 表达的机制尚不清楚。本综述旨在阐明 PPARγ 激动剂诱导 HO-1 表达的分子机制,并探讨它们如何防止炎症和氧化反应。